CoChat
Sign Up
Cited by 0Cervical Cancer and HPV ResearchWomen's cancer prevention and managementHIV/AIDS Research and Interventions

HPV Screening in Women Living with HIV (WLHIV) in Karnataka, India: Can it be Integrated into ART Centres?

Open access
Rao, Sripriya, R, Sankaranarayanan, Sarma, Divya, Nath, Ashwathy, R, Anuradha, Jagannathan, Latha, Rao, Anjali, Suhas, Guru +4 more·2025·Asian Pacific Journal of Cancer Prevention
DOI 10.31557/apjcp.2025.26.12.4513PMC PMC13242549
Open this paper in CoChat — free accountOpen PDF

Abstract

BACKGROUND: Women living with HIV (WLHIV) face a six-to-tenfold increased risk of cervical cancer due to higher HPV prevalence and persistence. Despite an estimated 1.05 million WLHIV in India and a vast National AIDS Control Programme (NACP) network, no organized cervical screening exists within this infrastructure. OBJECTIVE: This pilot implementation project aimed to demonstrate a feasible and efficacious model for integrating cervical cancer prevention services, including HPV screening and a 'see and treat' approach, for WLHIV within or near ART centres in hard-to-reach Indian settings. METHODS: A total of 368 WLHIV aged >21 years on ART from three centres were invited. 314 (85.3%) were screened using the COBAS 6800 high-risk HPV test. HPV-positive women were recalled for colposcopy using a portable digital device. A 'see and treat' approach was applied, using thermal ablation or LLETZ for minor/major lesions suggestive of precancer in field clinics. RESULT: 76 of 314 screened women (24.2%) tested positive for high-risk HPV. 65 of 76 HPV positive women (85.5%) complied with colposcopy and treatment. Histology from these 65 women showed 17 high-grade squamous intraepithelial lesions (HSIL), 23 low-grade SIL (LSIL), and 2 invasive cancers. The overall prevalence of HSIL or worse lesions was 5.7% among screened WLHIV. High participation was observed despite logistical challenges. CONCLUSION: The study confirms the significant burden of cervical neoplasia in WLHIV and demonstrates the feasibility and importance of integrating HPV screening and 'see and treat' services within or near existing ART centres using portable technologies. Leveraging the extensive NACP network offers a strategic opportunity for nationwide implementation, crucial for cervical cancer elimination efforts in this high-risk population.

AI snapshot

Written from the paper’s full text.

TL;DR

This pilot implementation project in Karnataka, India, integrated high-risk HPV screening and a “see-and-treat” approach for women living with HIV within or near ART centres. Among 314 screened WLHIV, 24.2% were hrHPV-positive and 5.7% had HSIL or worse lesions, supporting feasibility despite logistical and overtreatment challenges.

Key findings

  • Of 368 invited WLHIV, 314 (85.3%) underwent hrHPV screening; 76 (24.2%) tested positive for high-risk HPV.
  • Of 76 HPV-positive women, 65 (85.5%) complied with colposcopy/treatment; histology showed 17 HSIL, 23 LSIL, 2 invasive cancers, and 23 inflammation/metaplasia. Overall prevalence was 5.7% for HSIL or worse and 13.3% for LSIL or worse among screened WLHIV.
  • HPV 16 was the most prevalent type, detected in 31 women (40.8% of HPV-positive cases), including 16 (21.0%) as a sole infection; HPV 18 was found in 8 women (10.5%).
  • Among 64 HPV-positive women with colposcopic abnormalities treated in field clinics, 43 received thermal ablation and 21 received LLETZ; one additional woman with clinical features of invasive cancer was referred for cancer management.

Methods

  • Pilot implementation project with a cross-sectional design in Koppal district, Karnataka, India; participants were WLHIV aged >21 years on ART from three ART centres (Gangavathi, Koppal, and Gadag), invited from a larger NGO cohort of about 4,000 WLHIV.
  • Screening used the COBAS 6800 high-risk HPV DNA test for 14 HPV types; HPV-positive women were recalled for colposcopy using a portable digital MobileODT device, with a “see-and-treat” policy using thermal ablation or LLETZ for minor/major lesions.
  • Data were collected via case report forms, entered into the Karkinos Web Application, and analyzed in SPSS Statistics 28, primarily reporting frequencies of outcomes.

Limitations

  • The paper states the cross-sectional design provides only a single time-point assessment, the pilot was smaller than a full roll-out, and the specific hard-to-reach Koppal setting may limit generalisability to other regions.
  • The paper states the “see-and-treat” strategy led to overtreatment of approximately one-third of treated women without histological evidence of precancer, mostly inflammation or metaplasia, and CD4 count at ART registration was unavailable for 31.5% of screened women.
  • Evident from the text: treatment allocation was not randomized, long-term follow-up and cost-effectiveness outcomes are not reported, and participation may have been influenced by prior NGO engagement and community outreach.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.31557/apjcp.2025.26.12.4513

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Claims the paper makes

42 of 81 cited sources checked · 10 supported · 3 flagged · accuracy not yet measured

  • Premisecitation

    Women living with HIV face a six-to-tenfold increased risk of cervical cancer compared to HIV-negative women.

    “Women living with HIV (WLHIV) face an almost six-to-ten-fold increased risk of cervical cancer compared to HIV-negative women [8–10].”
    Quote in the paperSubstantial claim3 of 3 sources checked
    • cites [8] Chaturvedi AK Madeleine MM Biggar RJ Engels EA Risk of human papillomavirus-associated cancers among persons with aids J Natl Cancer Inst 2009 101 16 1120 30 19648510 PMC2728745 source

      Table 2 reports an approximately sixfold risk of invasive cervical cancer (SIR 5.6) among women with AIDS compared with the general population. Its approximately ninefold figure (SIR 8.9) is for in situ cervical cancer, not invasive cancer. The paper does not establish a six-to-tenfold risk for all women living with HIV compared specifically with HIV-negative women. (LLM, conf=0.87)

      Experimental — accuracy not yet measured
    • cites [9] Dhokotera T Bohlius J Spoerri A Egger M Ncayiyana J Olago V The burden of cancers associated with hiv in the south african public health sector, 2004-2014: A record linkage study Infect Agent Cancer. 2019 14 12 31073325 PMC6500038 source

      The Results (Table 2; page unavailable) report a higher cervical-cancer association among people living with HIV, but the adjusted odds ratio is 1.70 (95% CI 1.63–1.77), not six- to tenfold. The paper also reports odds, rather than a six- to tenfold increase in risk. (LLM, conf=0.90)

      Checked by a reasoning model — may be wrong.

      Experimental — accuracy not yet measured
    • cites [10] Korn AK Muzingwani L O’Bryan G Ensminger A Boylan AD Kafidi EL Cervical cancer screening and treatment, hiv infection, and age: Program implementation in seven regions of namibia PLoS One 2022 17 2 e0263920 35171941 PMC8849510 source

      The Introduction says women living with HIV have heightened cervical cancer risk, citing data showing up to a six-fold increase in incidence compared with HIV-negative women. It does not support the claimed upper end of ten-fold. (LLM, conf=0.88)

      Experimental — accuracy not yet measured
  • Premisecitation

    Persistent infection with one of the 14 high-risk HPV types is the necessary cause of cervical cancer.

    “Persistent infection with one of the 14 high-risk human papillomaviruses (hrHPV) is the necessary cause of cervical cancer [1, 2].”
    Quote in the paperSubstantial claim1 of 2 sources checked
    • cites [1] IARC W IARC monographs on the evaluation of carcinogenic risks to humans 2007 Geneva

      Couldn’t be matched to a paper in Crossref, so it can’t be checked.

    • cites [2] Mathur P Sathishkumar K Chaturvedi M Das P Sudarshan KL Santhappan S Cancer statistics, 2020: Report from national cancer registry programme, india JCO Glob Oncol. 2020 6 1063 75 32673076 PMC7392737 source

      The Discussion and Results discuss cervical cancer incidence, stage at diagnosis, and treatment, but do not address its cause. Searches for persistent infection, high-risk HPV, and papillomavirus found no passage supporting the claimed necessary cause or the number of HPV types. (LLM, conf=0.76)

      Experimental — accuracy not yet measured
  • Premisecitation

    The increased sensitivity of HPV testing for cervical precancerous lesions is due to earlier detection rather than overdiagnosis.

    “The increased sensitivity of HPV testing for cervical precancerous lesions has been shown to be due to earlier detection rather than overdiagnosis [22–25].”
    Quote in the paperSubstantial claim2 of 4 sources checked
    • cites [22] Sankaranarayanan R Nene BM Shastri SS Jayant K Muwonge R Budukh AM Hpv screening for cervical cancer in rural india N Engl J Med 2009 360 14 1385 94 19339719 source
    • cites [23] Dillner J Rebolj M Birembaut P Petry KU Szarewski A Munk C Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: Joint european cohort study Bmj. 2008 337 a1754 18852164 PMC2658827 source

      The Discussion (Limitations and other considerations) says that some HPV-positive results that initially appear false positive prove to be earlier detections of CIN3+. But it says longer follow-up attenuates overdiagnosis, not that overdiagnosis is absent. The Introduction likewise says increased sensitivity is “not merely overdiagnosis,” a narrower claim than “rather than overdiagnosis.” (LLM, conf=0.86)

      Experimental — accuracy not yet measured
    • cites [24] Joshi S Sankaranarayanan R Muwonge R Kulkarni V Somanathan T Divate U Screening of cervical neoplasia in hiv-infected women in india Aids 2013 27 4 607 15 23079814 source
    • cites [25] Viviano M DeBeaudrap P Tebeu PM Fouogue JT Vassilakos P Petignat P A review of screening strategies for cervical cancer in human immunodeficiency virus-positive women in sub-saharan africa Int J Womens Health. 2017 9 69 79 28203108 PMC5298303 source

      The HPV testing section states that HPV testing is more sensitive than cytology for identifying cervical precancerous lesions, though less specific (page not available in our copy). It does not say that the greater sensitivity results from earlier detection rather than overdiagnosis. (LLM, conf=0.86)

      Experimental — accuracy not yet measured
  • Interpretationcitation

    Cervical cancer screening is an essential and independent preventive intervention for women living with HIV.

    “Therefore, cervical cancer screening is an essential and independent preventive intervention for WLHIV [18].”
    Quote in the paperSubstantial claim1 of 1 sources checked
    • cites [18] Liu G Sharma M Tan N Barnabas RV Hiv-positive women have higher risk of human papilloma virus infection, precancerous lesions, and cervical cancer Aids 2018 32 6 795 808 29369827 PMC5854529 source
  • Premiseown data

    HPV testing demonstrates superior sensitivity in detecting high-grade cervical lesions among WLHIV.

    “HPV testing demonstrates superior sensitivity in detecting high-grade cervical lesions among women living with HIV (WLHIV).”
    Quote in the paperSubstantial claim3 of 5 sources checked
    • cites [21] Boddu A Bhatla N Vashist S Mathur S Mahey R Natarajan J Cervical cancer screening in hiv-positive women in india: Why, when and how? J Obstet Gynaecol India 2021 71 3 304 12 34408351 PMC8310826 source
    • cites [22] Sankaranarayanan R Nene BM Shastri SS Jayant K Muwonge R Budukh AM Hpv screening for cervical cancer in rural india N Engl J Med 2009 360 14 1385 94 19339719 source
    • cites [24] Joshi S Sankaranarayanan R Muwonge R Kulkarni V Somanathan T Divate U Screening of cervical neoplasia in hiv-infected women in india Aids 2013 27 4 607 15 23079814 source
    • cites [25] Viviano M DeBeaudrap P Tebeu PM Fouogue JT Vassilakos P Petignat P A review of screening strategies for cervical cancer in human immunodeficiency virus-positive women in sub-saharan africa Int J Womens Health. 2017 9 69 79 28203108 PMC5298303 source
    • cites [27] Kuhn L Saidu R Boa R Tergas A Moodley J Persing D Clinical evaluation of modifications to a human papillomavirus assay to optimise its utility for cervical cancer screening in low-resource settings: A diagnostic accuracy study Lancet Glob Health 2020 8 2 e296 e304 31981559 PMC8720235 source

      The Results (page unavailable) report 93.6% sensitivity for HPV DNA testing to detect CIN2+ in HIV-positive women. The Discussion (page unavailable) says cytology is less sensitive than HPV testing, but the paper does not report a direct comparison with cytology among women living with HIV. It therefore supports high sensitivity in this group, not the full claim of superior sensitivity within the group. (LLM, conf=0.83)

      Experimental — accuracy not yet measured
  • May combine two claims. 23
  • Classified as probably not a substantial claim. 28

  • May combine two claims.

    Premisecitation

    In a cohort of 1128 WLHIV, HPV testing achieved a sensitivity of 94.5% for detecting LSIL or worse, outperforming VIA (83.6%) and Pap smear (63.3%).

    “In a cohort of 1128 WLHIV, HPV testing achieved a sensitivity of 94.5% for detecting LSIL or worse, outperforming VIA (83.6%) and Pap smear (63.3%).”
    Quote in the paperSubstantial claim3 of 5 sources checked
    • cites [21] Boddu A Bhatla N Vashist S Mathur S Mahey R Natarajan J Cervical cancer screening in hiv-positive women in india: Why, when and how? J Obstet Gynaecol India 2021 71 3 304 12 34408351 PMC8310826 source

      The Results (Table 4; page unavailable) report sensitivities for detecting CIN2+ in HIV-positive women of 91.7% for HPV and 75.0% for both VIA and Pap smear—not the claimed values or VIA outperforming Pap. Another Results passage states that the study included 202 HIV-positive subjects, not a cohort of 1,128. The paper does not report these figures for LSIL or worse. (LLM, conf=0.90)

      Checked by a reasoning model — may be wrong.

      Experimental — accuracy not yet measured
    • cites [22] Sankaranarayanan R Nene BM Shastri SS Jayant K Muwonge R Budukh AM Hpv screening for cervical cancer in rural india N Engl J Med 2009 360 14 1385 94 19339719 source
    • cites [24] Joshi S Sankaranarayanan R Muwonge R Kulkarni V Somanathan T Divate U Screening of cervical neoplasia in hiv-infected women in india Aids 2013 27 4 607 15 23079814 source
    • cites [25] Viviano M DeBeaudrap P Tebeu PM Fouogue JT Vassilakos P Petignat P A review of screening strategies for cervical cancer in human immunodeficiency virus-positive women in sub-saharan africa Int J Womens Health. 2017 9 69 79 28203108 PMC5298303 source

      The HPV testing section states that HPV testing is more sensitive than cytology for cervical precancerous lesions, and it describes an advantage over VIA in a screen-and-treat trial. Our copy does not substantiate a cohort of 1,128 women, an LSIL-or-worse endpoint, or the three stated sensitivity percentages (searched: 1128, 94.5%, LSIL, and Table 2). (LLM, conf=0.84)

      Experimental — accuracy not yet measured
    • cites [27] Kuhn L Saidu R Boa R Tergas A Moodley J Persing D Clinical evaluation of modifications to a human papillomavirus assay to optimise its utility for cervical cancer screening in low-resource settings: A diagnostic accuracy study Lancet Glob Health 2020 8 2 e296 e304 31981559 PMC8720235 source

      The Methods (Study population; page unavailable) report 535 women living with HIV, not 1128. The Results (page unavailable) give HPV-test sensitivity as 93.6% for CIN2+, not 94.5% for LSIL or worse; the paper does not report the claimed VIA and Pap-smear comparison. (LLM, conf=0.90)

      Checked by a reasoning model — may be wrong.

      Experimental — accuracy not yet measured

  • May combine two claims.

    Premisecitation

    India's National AIDS Control Programme includes a network of over 2500 ART centres providing regular care to over a million people living with HIV.

    “which includes a network of over 2500 ART centres (including ART centres, link ART centres, and care support centres) providing regular care to over a million people living with HIV across the country [8, 10, 13].”
    Quote in the paperSubstantial claim2 of 3 sources checked
    • cites [8] Chaturvedi AK Madeleine MM Biggar RJ Engels EA Risk of human papillomavirus-associated cancers among persons with aids J Natl Cancer Inst 2009 101 16 1120 30 19648510 PMC2728745 source

      The paper’s Results describe 499,230 people with AIDS in the United States, not India’s HIV-care network. Searches for India’s National AIDS Control Programme, 2,500 ART centres, and care for over a million people found no passage addressing those claims in our copy. (LLM, conf=0.78)

      Experimental — accuracy not yet measured
    • cites [10] Korn AK Muzingwani L O’Bryan G Ensminger A Boylan AD Kafidi EL Cervical cancer screening and treatment, hiv infection, and age: Program implementation in seven regions of namibia PLoS One 2022 17 2 e0263920 35171941 PMC8849510 source

      The Introduction and Conclusions discuss cervical cancer screening integrated with HIV services in Namibia, not India's National AIDS Control Programme. Searches for India, 2,500 ART centres, and the number of people receiving care found no passage addressing the cited figures. (LLM, conf=0.77)

      Experimental — accuracy not yet measured
    • cites [13] UNAIDS Anti-retroviral therapy coverage (% of people living with HIV) - India [Internet] Available from: https://data.worldbank.org/indicator/SH.HIV.ARTC.ZS?locations=IN

      Couldn’t be matched to a paper in Crossref, so it can’t be checked.

  • Classified as probably not a substantial claim. May combine two claims.

    Premisecitation

    Nearly all cervical cancers harbour HPV DNA, particularly oncogenic sequences such as E6 and E7.

    “Nearly all cervical cancers harbour HPV DNA, particularly oncogenic sequences such as E6 and E7, emphasizing the causal role of persistent HPV infection in cervical carcinogenesis [5, 6].”
    Quote in the paperSubstantial claim1 of 2 sources checked
    • cites [5] Gheit T Vaccarella S Schmitt M Pawlita M Franceschi S Sankaranarayanan R Prevalence of human papillomavirus types in cervical and oral cancers in central india Vaccine 2009 27 5 636 9 19056450 source
    • cites [6] Kraus I Molden T Holm R Lie AK Karlsen F Kristensen GB Presence of e6 and e7 mrna from human papillomavirus types 16, 18, 31, 33, and 45 in the majority of cervical carcinomas J Clin Microbiol 2006 44 4 1310 7 16597856 PMC1448674 source

      The Abstract reports 97% overall HPV prevalence in 204 invasive cervical squamous cell carcinomas, with HPV DNA detected by each PCR method in about 92% and E6/E7 transcripts detected in 92%. It also identifies E6 and E7 as oncogenic HPV genes. The claim extends these findings from squamous cell carcinomas to cervical cancers generally, which this study did not assess. (LLM, conf=0.84)

      Experimental — accuracy not yet measured

  • Classified as probably not a substantial claim. May combine two claims.

    Premisecitation

    Cervical HPV infection is common and typically clears or becomes latent within two years, but a subset of infections persists.

    “While cervical HPV infection is common and typically clears or becomes latent within two years, a subset of infections persists [6, 7].”
    Quote in the paperSubstantial claim1 of 2 sources checked
    • cites [6] Kraus I Molden T Holm R Lie AK Karlsen F Kristensen GB Presence of e6 and e7 mrna from human papillomavirus types 16, 18, 31, 33, and 45 in the majority of cervical carcinomas J Clin Microbiol 2006 44 4 1310 7 16597856 PMC1448674 source

      The Abstract says the lifetime risk of HPV infection is 80% and discusses identifying persistent infections; the Discussion says most cervical viral infections produce transient low-grade lesions. These passages support common infection, a typically transient course, and persistence in some cases. They do not say that infections clear or become latent within two years. (LLM, conf=0.86)

      Experimental — accuracy not yet measured
    • cites [7] Ho GY Bierman R Beardsley L Chang CJ Burk RD Natural history of cervicovaginal papillomavirus infection in young women N Engl J Med 1998 338 7 423 8 9459645 source

  • May combine two claims.

    Premisecitation

    HPV testing has high sensitivity for detecting precancerous lesions in WLHIV and inherent advantages of objectivity and reproducibility compared to visual inspection methods like VIA or subjective assessments like cytology.

    “The rationale for this choice lies in HPV testing’s high sensitivity for detecting precancerous lesions in WLHIV and its inherent advantages of objectivity and reproducibility compared to visual inspection methods like VIA or subjective assessments like cytology [19–23].”
    Quote in the paperSubstantial claim3 of 5 sources checked
    • cites [19] Arbyn M Ronco G Anttila A Meijer CJ Poljak M Ogilvie G Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer Vaccine. 2012 30 Suppl 5 F88 99 23199969 source
    • cites [20] Elfström K Smelov V Johansson A Eklund C Naucler P Arnheim Dahlström L Long term duration of protective effect for hpv negative women: Follow-up of primary hpv screening randomised controlled trial BMJ (Clinical research ed). 2014 348 g130 PMC3898575 24435414 source

      The Introduction states that HPV DNA testing has higher sensitivity for detecting cervical intraepithelial neoplasia, and the Results report sensitivity for CIN2+ and CIN3+. The paper does not establish that finding specifically in women living with HIV, nor does it compare HPV testing’s objectivity or reproducibility with VIA or cytology. (LLM, conf=0.88)

      Experimental — accuracy not yet measured
    • cites [21] Boddu A Bhatla N Vashist S Mathur S Mahey R Natarajan J Cervical cancer screening in hiv-positive women in india: Why, when and how? J Obstet Gynaecol India 2021 71 3 304 12 34408351 PMC8310826 source

      The Results report that HPV testing detected CIN2+ lesions in HIV-positive women with 91.7% sensitivity, versus 75.0% for both Pap smear and VIA. The Materials and Methods describe a numerical threshold for a positive HPV test, but the paper does not establish that HPV testing is more objective or reproducible than VIA or cytology. (LLM, conf=0.88)

      Experimental — accuracy not yet measured
    • cites [22] Sankaranarayanan R Nene BM Shastri SS Jayant K Muwonge R Budukh AM Hpv screening for cervical cancer in rural india N Engl J Med 2009 360 14 1385 94 19339719 source
    • cites [23] Dillner J Rebolj M Birembaut P Petry KU Szarewski A Munk C Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: Joint european cohort study Bmj. 2008 337 a1754 18852164 PMC2658827 source

      The Introduction reports that HPV tests have higher sensitivity than cytology for detecting high-grade cervical lesions and that cytology has limited reproducibility. It does not establish those advantages specifically in women living with HIV, or compare HPV testing’s objectivity or reproducibility with visual inspection methods such as VIA. (LLM, conf=0.88)

      Experimental — accuracy not yet measured

  • May combine two claims.

    Premisecitation

    HPV testing has practical advantages such as limited training requirements and the potential for self-sampling that ease the burden on healthcare resources, making it suitable for resource-limited settings.

    “Furthermore, practical advantages such as limited training requirements and the potential for self-sampling ease the burden on healthcare resources, making it suitable for resource-limited settings [22, 24–26].”
    Quote in the paperNot a substantial claim2 of 4 sources checked
    • cites [22] Sankaranarayanan R Nene BM Shastri SS Jayant K Muwonge R Budukh AM Hpv screening for cervical cancer in rural india N Engl J Med 2009 360 14 1385 94 19339719 source
    • cites [24] Joshi S Sankaranarayanan R Muwonge R Kulkarni V Somanathan T Divate U Screening of cervical neoplasia in hiv-infected women in india Aids 2013 27 4 607 15 23079814 source
    • cites [25] Viviano M DeBeaudrap P Tebeu PM Fouogue JT Vassilakos P Petignat P A review of screening strategies for cervical cancer in human immunodeficiency virus-positive women in sub-saharan africa Int J Womens Health. 2017 9 69 79 28203108 PMC5298303 source

      The HPV testing section says self-sampling could improve screening coverage in low- and middle-income countries where infrastructure and health personnel are limited. It also describes point-of-care HPV tests that require limited infrastructure. The passages do not establish that HPV testing requires limited training, so that part of the attributed claim is unsupported. (LLM, conf=0.85)

      Experimental — accuracy not yet measured
    • cites [26] Sahasrabuddhe VV Bhosale RA Joshi SN Kavatkar AN Nagwanshi CA Kelkar RS Prevalence and predictors of colposcopic-histopathologically confirmed cervical intraepithelial neoplasia in hiv-infected women in india PLoS One 2010 5 1 e8634 20072610 PMC2798747 source

      The Methods (Study Procedures; page unavailable) report that participants provided self-collected vaginal swabs for HPV testing. The Discussion (page unavailable) describes a push for low-cost, rapid HPV tests in developing countries, but says testing was then unavailable or unaffordable for most women there. The paper does not establish that HPV testing requires limited training or that these advantages reduce healthcare-resource burdens. (LLM, conf=0.87)

      Experimental — accuracy not yet measured

  • May combine two claims.

    Premisecitation

    ART lowers progression from normal cytology to LSIL but not to HSIL, and cervical cancer incidence has not been lowered by ART.

    “ART has been shown to lower progression from normal cytology to LSIL but not to HSIL, and critically, cervical cancer incidence has not been lowered by ART.”
    Quote in the paperSubstantial claim1 of 1 sources checked
    • cites [18] Liu G Sharma M Tan N Barnabas RV Hiv-positive women have higher risk of human papilloma virus infection, precancerous lesions, and cervical cancer Aids 2018 32 6 795 808 29369827 PMC5854529 source

  • Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

    Premisecitation

    Policy recommendations for HPV DNA testing exist in some African nations, but widespread implementation is still pending.

    “While policy recommendations for HPV DNA testing exist in some African nations, widespread implementation is still pending [10, 36].”
    Quote in the paperNot a substantial claim2 of 2 sources checked
    • cites [10] Korn AK Muzingwani L O’Bryan G Ensminger A Boylan AD Kafidi EL Cervical cancer screening and treatment, hiv infection, and age: Program implementation in seven regions of namibia PLoS One 2022 17 2 e0263920 35171941 PMC8849510 source

      The Introduction (page not available) says HPV DNA testing was not yet available in Namibian public health facilities, and the Conclusions say widespread HPV testing was not yet feasible. But the paper describes Namibia’s screening policy as relying on VIA; it does not establish that some African nations have policy recommendations for HPV DNA testing. (LLM, conf=0.86)

      Experimental — accuracy not yet measured
    • cites [36] Asangbeh-Kerman SL Davidović M Taghavi K Kachingwe J Rammipi KM Muzingwani L Cervical cancer prevention in countries with the highest hiv prevalence: A review of policies BMC Public Health 2022 22 1 1530 35948944 PMC9367081 source

  • May combine two claims.

    Premisecitation

    In India, hrHPV prevalence exceeds 20% and HSIL+ lesions occur in over 5% of screened WLHIV.

    “Our findings align with prior studies in India, reporting hrHPV prevalence exceeding 20% and HSIL+ lesions in over 5% of screened WLHIV [21, 24, 26].”
    Quote in the paperNot a substantial claim2 of 3 sources checked
    • cites [21] Boddu A Bhatla N Vashist S Mathur S Mahey R Natarajan J Cervical cancer screening in hiv-positive women in india: Why, when and how? J Obstet Gynaecol India 2021 71 3 304 12 34408351 PMC8310826 source

      The Results report hrHPV in 37.6% of screened HIV-positive women, supporting the first figure. They report HSIL cytology in 4.5%, not over 5%; the 6.4% figure is for histologically diagnosed CIN2+ lesions, a different measure. (LLM, conf=0.88)

      Experimental — accuracy not yet measured
    • cites [24] Joshi S Sankaranarayanan R Muwonge R Kulkarni V Somanathan T Divate U Screening of cervical neoplasia in hiv-infected women in india Aids 2013 27 4 607 15 23079814 source
    • cites [26] Sahasrabuddhe VV Bhosale RA Joshi SN Kavatkar AN Nagwanshi CA Kelkar RS Prevalence and predictors of colposcopic-histopathologically confirmed cervical intraepithelial neoplasia in hiv-infected women in india PLoS One 2010 5 1 e8634 20072610 PMC2798747 source

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Findingown data

    21 women had LLETZ.

    “43 had thermal ablation and 21 women had LLETZ”
    Quote in the paperNot a substantial claim

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Findingown data

    Almost half of the women travelled more than 40 km to reach the screening clinic.

    “almost half of the women travelled more than 40 kms to reach the screening clinic.”
    Quote in the paperNot a substantial claim

  • May combine two claims.

    Findingown data

    All women accepted treatment and had no side effects except two.

    “All the women accepted the treatment and had no side effects except two”
    Quote in the paperSubstantial claim

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Findingown data

    Among women receiving ART, two thirds received it for more than 5 years.

    “Among women receiving ART, two thirds received it for more than 5 years.”
    Quote in the paperNot a substantial claim

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Findingown data

    294 (93.6%) were known to be on ART for 1 to 20 years.

    “294 (93.6%) were known to be on ART for a period varying from 1 to 20 years duration”
    Quote in the paperNot a substantial claim

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Findingown data

    One woman had bleeding after LLETZ which was managed conservatively by vaginal packs.

    “one woman had bleeding after LLETZ which was managed conservatively by vaginal packs”
    Quote in the paperNot a substantial claim

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Findingown data

    Around three fourths of screened women worked as agricultural labourers or daily wagers in manual work.

    “around three fourths worked as agricultural labourers or as daily wagers engaged in other manual work such as construction”
    Quote in the paperNot a substantial claim

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Findingown data

    CD4 count on registration was not available for 99 (31.5%) of women living with HIV in the study.

    “The details of CD 4 count on registration at ART centres were not available for 99 (31.5%) of WLHIV in the study.”
    Quote in the paperNot a substantial claim

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Findingown data

    One woman had a fainting attack after thermal ablation due to hypoglycemia which was managed conservatively.

    “another woman had a fainting attack after thermal ablation which was essentially due to hypoglycemia which was managed conservatively.”
    Quote in the paperNot a substantial claim

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Findingown data

    Half of the screened women were between 31-40 years old.

    “Half of the screened women were between 31-40 years old”
    Quote in the paperNot a substantial claim

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Findingown data

    43 women had thermal ablation.

    “43 had thermal ablation and 21 women had LLETZ”
    Quote in the paperNot a substantial claim

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Findingown data

    One woman who had clinical features of cancer was referred for cancer management after taking biopsies.

    “One woman who had clinical features of cancer was referred for cancer management after taking biopsies.”
    Quote in the paperNot a substantial claim

  • May combine two claims.

    Findingown data

    Our findings confirm the high risk of HPV infection and cervical neoplasia in WLHIV.

    “Our findings confirm the high risk of HPV infection and cervical neoplasia in WLHIV and demonstrate the feasibility of providing the entire continuum of care via. screening, triaging, diagnosis, and treatment using portable point-of-care devices within or near the ART centre structure.”
    Quote in the paperSubstantial claim

  • Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

    Premisecitation

    HPV16 alone causes around 63-81% of cervical cancers in the general population and HPV18 accounts for another 10-15% in India.

    “Among the oncogenic HPV types, HPV16 alone causes around 63-81% of cervical cancers in the general population and HPV18 accounts for another 10 to 15% in India [3–5].”
    Quote in the paperNot a substantial claim0 of 3 sources checked
    • cites [3] Basu P Roychowdhury S Bafna UD Chaudhury S Kothari S Sekhon R Human papillomavirus genotype distribution in cervical cancer in india: Results from a multi-center study Asian Pac J Cancer Prev 2009 10 1 27 34 19469620
    • cites [4] Deodhar K Gheit T Vaccarella S Romao CC Tenet V Nene BM Prevalence of human papillomavirus types in cervical lesions from women in rural western india J Med Virol 2012 84 7 1054 60 22585722 source
    • cites [5] Gheit T Vaccarella S Schmitt M Pawlita M Franceschi S Sankaranarayanan R Prevalence of human papillomavirus types in cervical and oral cancers in central india Vaccine 2009 27 5 636 9 19056450 source

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Interpretationreasoning

    The increased risk translates to approximately 1500 new cervical cancer cases annually among women living with HIV in India.

    “we estimate this increased risk translates to approximately 1500 new cervical cancer cases annually in this population [11, 12].”
    Quote in the paperNot a substantial claim0 of 2 sources checked
    • cites [11] NACO ICMR- National Institute of Medical Statistics. India HIV Estimates 2021: Fact Sheet 2022 New Delhi

      Couldn’t be matched to a paper in Crossref, so it can’t be checked.

    • cites [12] Sung H Ferlay J Laversanne M Global Cancer Observatory: Cancer Today – India fact sheet (GLOBOCAN 2022) [Internet] 2022 Lyon, France

      Couldn’t be matched to a paper in Crossref, so it can’t be checked.

    • Rests on an assumption: The six-to-tenfold increased risk of cervical cancer observed in women living with HIV applies to the Indian women living with HIV population.

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Premisecitation

    In India, there are an estimated 1.05 million women living with HIV.

    “In India, home to an estimated 1.05 million WLHIV”
    Quote in the paperNot a substantial claim0 of 2 sources checked
    • cites [11] NACO ICMR- National Institute of Medical Statistics. India HIV Estimates 2021: Fact Sheet 2022 New Delhi

      Couldn’t be matched to a paper in Crossref, so it can’t be checked.

    • cites [12] Sung H Ferlay J Laversanne M Global Cancer Observatory: Cancer Today – India fact sheet (GLOBOCAN 2022) [Internet] 2022 Lyon, France

      Couldn’t be matched to a paper in Crossref, so it can’t be checked.

  • Probably not a substantial claim: may not pass S2 (checkable).

    Interpretationreasoning

    Leveraging the extensive NACP network offers a strategic opportunity for nationwide implementation of cervical cancer prevention.

    “Leveraging the extensive NACP network offers a strategic opportunity for nationwide implementation, crucial for cervical cancer elimination efforts in this high-risk population.”
    Quote in the paperNot a substantial claim
    • Rests on an assumption: There is currently no organised cervical screening available for women living with HIV in India.

  • Classified as probably not a substantial claim.

    Interpretationown data

    The prevalence of HSIL or worse emphasizes the urgent need for effective screening strategies in this population.

    “This prevalence emphasizes the urgent need for effective screening strategies in this population.”
    Quote in the paperSubstantial claim

  • Probably not a substantial claim: may not pass S2 (checkable).

    Interpretationown data

    These results have significant implications for cervical cancer prevention strategies in high-risk populations across low- and middle-income countries.

    “These results have significant implications for cervical cancer prevention strategies in high-risk populations across low- and middle-income countries (LMICs).”
    Quote in the paperNot a substantial claim

  • May combine two claims.

    Premisecitation

    HPV testing is the most preferred test according to recent WHO recommendations and is superior to cytology or VIA.

    “We chose to screen WLHIV in our study using HPV testing, which is the most preferred test according to recent WHO recommendations, superior to cytology or VIA [16].”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites [16] WHO World Health Organization [Internet] 2023 [cited 2025 May 12] Available from: https://www.who.int/

      Couldn’t be matched to a paper in Crossref, so it can’t be checked.

  • May combine two claims.

    Interpretationreasoning

    Engagement of local NGOs (e.g., Samraksha), targeted education, and navigation support were key enablers of screening compliance.

    “Engagement of local NGOs (e.g., Samraksha), targeted education, and navigation support were key enablers.”
    Quote in the paperSubstantial claim

  • Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

    Premisecitation

    India's ART programme, the second largest globally, has led to a decline in adult HIV prevalence and AIDS-related mortality.

    “India’s ART programme, second largest globally, has led to a decline in adult HIV prevalence and AIDS-related mortality [14].”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites [14] NACO National guidelines for HIV care and treatment 2021 [Internet] 2023 Available from: https://naco.gov.in/sites/default/files/National_Guidelines_for_HIV_Care_and_Treatment_2021.pdf

      Couldn’t be matched to a paper in Crossref, so it can’t be checked.

  • Classified as probably not a substantial claim.

    Interpretationreasoning

    Leveraging India's existing ART infrastructure presents a real opportunity to prevent cervical cancer in a million WLHIV in India.

    “Leveraging this existing, accessible infrastructure presents a real opportunity to prevent cervical cancer in a million WLHIV in India.”
    Quote in the paperSubstantial claim

  • May combine two claims.

    Interpretationreasoning

    This pilot study highlights the feasibility and urgency of integrating cervical cancer screening and treatment into existing ART centres in India.

    “This pilot study highlights the feasibility and urgency of integrating cervical cancer screening and treatment into existing ART centres in India.”
    Quote in the paperNot a substantial claim
    • Rests on an assumption: Despite WHO recommendations and national policies endorsing HPV testing, implementation remains limited.

  • Classified as probably not a substantial claim.

    Interpretationreasoning

    India's 2500 ART centres represent a strategic platform for delivering see-and-treat cervical services to WLHIV.

    “Given their reach and infrastructure, India’s 2500 ART centres represent a strategic platform for delivering see-and-treat cervical services to women living with HIV (WLHIV).”
    Quote in the paperSubstantial claim

  • May combine two claims.

    Premisecitation

    The Government of India has massively scaled up and decentralised ART services since 2004, creating a globally acclaimed infrastructure that can effectively deliver integrated services.

    “The massive scale-up and decentralisation of ART services by the Government of India since 2004 has created a globally acclaimed infrastructure that can effectively deliver integrated services [14].”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites [14] NACO National guidelines for HIV care and treatment 2021 [Internet] 2023 Available from: https://naco.gov.in/sites/default/files/National_Guidelines_for_HIV_Care_and_Treatment_2021.pdf

      Couldn’t be matched to a paper in Crossref, so it can’t be checked.

  • Probably not a substantial claim: may not pass S2 (checkable). May combine two claims.

    Interpretationreasoning

    Urgent introduction of HPV screening and treatment using a see-and-treat approach, integrated into the existing NACO network, aligns with global evidence and WHO recommendations and is crucial to mitigate the disproportionately high risk faced by WLHIV.

    “Urgent introduction of HPV screening and treatment using a ‘see-and-treat’ approach, integrated into the existing NACO network, aligns with global evidence, WHO recommendations, and is crucial to mitigate the disproportionately high risk faced by WLHIV.”
    Quote in the paperNot a substantial claim
    • Rests on an assumption: Despite WHO recommendations and national policies endorsing HPV testing, implementation remains limited.

  • May combine two claims.

    Interpretationown data

    Integrating cervical cancer screening and treatment into India's ART centres is feasible and critically important.

    “Our experience strongly supports the feasibility and critical importance of integrating cervical cancer screening and treatment into India’s ART centres.”
    Quote in the paperSubstantial claim

  • Probably not a substantial claim: may not pass S2 (checkable). May combine two claims.

    Interpretationreasoning

    Embedding cervical screening within India's ART system aligns with global best practices and would advance national and global goals for cervical cancer elimination.

    “Embedding cervical screening within this system aligns with global best practices and would advance national and global goals for cervical cancer elimination.”
    Quote in the paperNot a substantial claim

  • May combine two claims.

    Premisecitation

    NACP has over 2500 ART centres providing care to approximately 1.4 million PLHIV across India.

    “The National AIDS Control Programme (NACP) offers an obvious and powerful platform for launching such services, leveraging its existing network of over 2500 ART centres providing care to approximately 1.4 million PLHIV across the country [13].”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites [13] UNAIDS Anti-retroviral therapy coverage (% of people living with HIV) - India [Internet] Available from: https://data.worldbank.org/indicator/SH.HIV.ARTC.ZS?locations=IN

      Couldn’t be matched to a paper in Crossref, so it can’t be checked.

  • May combine two claims.

    Interpretationown data

    Integrating HPV screening and treatment into ART centres is an effective and feasible strategy to reduce cervical cancer risk in WLHIV in India.

    “Integrating HPV screening and treatment into ART centres is presented as an effective and feasible strategy to reduce cervical cancer risk in WLHIV in India.”
    Quote in the paperSubstantial claim
    • Rests on an assumption: India's National AIDS Control Programme (NACP) is highly successful and extensive.
    • Rests on an assumption: HPV DNA testing is WHO-recommended for cervical cancer screening.
    • Rests on an assumption: The feasibility and compliance observed in the pilot can be replicated in other ART centres in India.
    • Rests on an assumption: Post-treatment HIV shedding is not a significant concern for women on ART who follow abstinence recommendations.
    • Rests on an assumption: The overtreatment of approximately one-third of treated women is acceptable given the benefits of the see-and-treat strategy.

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Interpretationnone given

    The study's focus on a specific geographical setting may limit the direct generalisability of the findings to other diverse regions within India, rather than the broader Asia-Pacific region.

    “Finally, the study’s focus on a specific geographical setting may limit the direct generalisability of the findings to other diverse regions within India, rather than the broader Asia-Pacific region”
    Quote in the paperNot a substantial claim

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Study design and conductown data

    CD4 count data at ART registration was unavailable for 31.5% of the screened women.

    “Furthermore, CD4 count data at ART registration was unavailable for a notable proportion (31.5%) of the screened women.”
    Quote in the paperNot a substantial claim

  • Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

    Study design and conductnone given

    The study's cross-sectional design offers a single time-point assessment and was implemented on a smaller scale than a full roll-out.

    “The study’s cross-sectional design offers a single time-point assessment and was implemented on a smaller scale than a full roll-out.”
    Quote in the paperNot a substantial claim
43 of 43

  • The paper relies on this without support.

    There is currently no organised cervical screening available for women living with HIV in India.

    “there is currently no organised cervical screening available for them in India.”

  • The paper relies on this without support.

    The 'see-and-treat' approach decreases attrition and improves adherence to treatment in this high-risk population.

    “This ‘see-and-treat’ approach was adopted in this high-risk population to decrease attrition and improve adherence to treatment.”

  • The paper relies on this without support.

    The six-to-tenfold increased risk of cervical cancer observed in women living with HIV applies to the Indian women living with HIV population.

    “we estimate this increased risk translates to approximately 1500 new cervical cancer cases annually in this population [11, 12].”

  • The paper relies on this without support.

    A negative HPV test offers greater reassurance of a low long-term risk of CIN 3 and invasive cancer compared to negative cytology or VIA, reducing the chance of missed lesions and delayed treatment.

    “A negative HPV test offers greater reassurance of a low long-term risk of CIN 3 and invasive cancer compared to negative cytology or VIA, reducing the chance of missed lesions and delayed treatment.”

  • The paper relies on this without support.

    For socio-economically disadvantaged WLHIV, travelling long distances involves lost wages and travel expenditures, making repeat visits a considerable barrier to completing the care pathway.

    “For this socio-economically disadvantaged population, travelling long distances involves lost wages and travel expenditures, making repeat visits a considerable barrier to completing the care pathway.”

  • The paper relies on this without support.

    The overtreatment rate in this study is comparable to previously documented rates with ablative treatments like cryotherapy in see-and-treat settings.

    “This rate is comparable to previously documented rates with ablative treatments like cryotherapy in ‘see-and-treat’ settings.”

  • The paper relies on this without support.

    Overtreatment has not been associated with adverse events during follow-up.

    “Previous studies have indicated that such overtreatment has not been associated with adverse events during follow-up.”

  • The paper relies on this without support.

    No increase in detectable cervical HIV-1 RNA after ablative treatment among HIV-positive women already on ART.

    “It has been reported no increase in detectable cervical HIV-1 RNA after ablative treatment among HIV-positive women already on ART.”

  • The paper relies on this without support.

    Despite WHO recommendations and national policies endorsing HPV testing, implementation remains limited.

    “Despite WHO recommendations and national policies endorsing HPV testing, implementation remains limited.”

  • The paper relies on this without support.

    India's National AIDS Control Programme (NACP) is highly successful and extensive.

    “India’s highly successful NACP”
    “India’s extensive National AIDS Control Programme (NACP) network”

  • The paper relies on this without support.

    HPV DNA testing is WHO-recommended for cervical cancer screening.

    “WHO-recommended HPV DNA testing”

  • The paper relies on this without support.

    The feasibility and compliance observed in the pilot can be replicated in other ART centres in India.

    “Integrating HPV screening and treatment into ART centres is presented as an effective and feasible strategy to reduce cervical cancer risk in WLHIV in India.”

  • The paper relies on this without support.

    Post-treatment HIV shedding is not a significant concern for women on ART who follow abstinence recommendations.

    “While potential concerns regarding increased post-treatment HIV shedding exist, particularly for women not on ART, this is likely less significant for those on ART with the recommendation of abstinence.”

  • The paper relies on this without support.

    The overtreatment of approximately one-third of treated women is acceptable given the benefits of the see-and-treat strategy.

    “Notably, the ‘see-and-treat’ strategy led to the overtreatment of approximately one-third of treated women, who presented without histological evidence of precancer, primarily showing inflammation or metaplasia.”
14 of 14

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

  • HSIL-or-worse prevalence does not match the reported cases

    Major

    The paper reports 17 HSIL cases and 2 invasive cancers among 314 screened women. Those 19 cases give an HSIL-or-worse prevalence of 6.1%, not 5.7%.

    Reported 5.7 · recomputed 6.050955

  • Management of women without visible lesions is contradictory

    Major

    The methods first say women without visible lesions were advised to return for repeat HPV testing, but later say those women were treated at the initial encounter.

  • Table 1 and Table 2 titles are swapped relative to their contents

    Minor

    The table titled demographic characteristics contains HPV-type counts, while the table titled HPV-type distribution contains demographic variables.

  • Referral count excludes one of two cancer patients

    Minor

    Figure 2 reports one cancer-management referral, but the results describe both a woman whose LLETZ revealed cancer and a separate woman with clinical features of cancer being referred.

  • Table 5 footnote misidentifies its carcinoma case

    Minor

    The asterisk on Table 5's carcinoma total identifies the included LLETZ patient, but its footnote describes the clinically apparent cancer patient who was referred after biopsy rather than included among the 64 field-clinic treatments.

  • Participant-flow treatment counts disagree with the results

    Minor

    Figure 2 assigns 45 women to thermal ablation and 19 to LLETZ, whereas the results and Table 5 assign 43 and 21, respectively.

  • HPV 18 count omits two coinfections

    Minor

    The HPV-type table lists 4 HPV 18-only cases, 3 with other types, 2 with HPV 16, and 1 with both HPV 16 and other types. These total 10 women with HPV 18, rather than 8.

    Reported 8 · recomputed 10

7 of 7

Cites

Flagged first, then by citations

5 of the 35 references couldn’t be matched to a known paper.

Authors
Rao, S., R, S., Sarma, D., Nath, A., R, A., Jagannathan, L., Rao, A., Suhas, G., Iyengar, S., V, R., Chhabra, M., & Ramachandran, V.
Affiliations
Indian Cancer Society (IN)
ORCID
Rao, Sripriya
Venue
Asian Pacific Journal of Cancer Prevention
Publisher
EpiSmart Science Vector Ltd
Published
2025-12-01
Volume
26
Issue
12
Pages
4513-4523
ISSN
  • 1513-7368 (ISSN-L)
  • 2476-762X
DOI
10.31557/apjcp.2025.26.12.4513
PMC
PMC13242549
OpenAlex
W7117503102
Semantic Scholar
610948dd650784e86866b41f40ef300e2f0ef838
Cited by
0
References
35
FWCI
0.00
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Asian Pacific Journal of Cancer Prevention (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • PubMed Central (submittedVersion, cc-by-nc)
Topics
  • Health Sciences › Medicine › Epidemiology › Cervical Cancer and HPV Research
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Women's cancer prevention and management
  • Health Sciences › Medicine › Infectious Diseases › HIV/AIDS Research and Interventions
Keywords
HPV testing, women living with HIV, cervical cancer prevention, art centers, service integration, see and treat, colposcopy, high-risk HPV prevalence, high-grade squamous intraepithelial lesion, thermal ablation, LLETZ, National AIDS Control Programme, hard-to-reach populations, Karnataka
MeSH terms
Adult, Uterine Cervical Dysplasia, Uterine Cervical Neoplasms, Colposcopy, Female, Follow-Up Studies, HIV, Humans, India, Mass Screening, Middle Aged, Pilot Projects, Prognosis, HIV Infections, Papillomaviridae, Papillomavirus Infections, Early Detection of Cancer, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Claims read by deepseek-v4.1-flash under definition version 3 (extract-v3) on 2026-10-16.

Classified by jev-1.13-20260917 (gold-guideline-v0.2) on 2026-10-16.

Cited sources are checked by gpt-6-sol.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review